BACKGROUND: It is suggested that the integration of maximal myocardial blood flow (MBF) and coronary flow reserve (CFR), termed coronary flow capacity, allows for comprehensive evaluation of patients with known or suspected stable coronary artery disease. Because management decisions are predicated on clinical risk, we sought to determine the independent and integrated value of maximal MBF and CFR for predicting cardiovascular death.
C
ardiovascular disease is the leading cause of mortality worldwide, with ischemic heart disease accounting for >50% of cardiovascular deaths. 1, 2 In recent years, it has been demonstrated that, in addition to coronary artery disease (CAD) of the epicardial vessels, dysfunction of the coronary microcirculation contributes to the increased cardiovascular morbidity and mortality. [3] [4] [5] Coronary flow reserve (CFR), the ratio of maximal myocardial blood flow (MBF) during pharmacologically induced coronary vasodilation to resting MBF, is an integrated measure of flow through both the large epicardial coronary arteries and the microcirculation. 6 CFR has been proposed as an indirect parameter to evaluate the function of the coronary circulation, and its impairment is a strong predictor of cardiovascular mortality. [7] [8] [9] [10] [11] However, CFR can be impaired because of a decrease in maximal MBF or an increase in resting MBF. Therefore, it has been proposed that the integration of CFR with maximal MBF, termed coronary flow capacity, could allow for comprehensive evaluation of patients with known or suspected stable CAD compared with CFR alone. [12] [13] [14] Because management decisions, including the decision to revascularize, are predicated on clinical risk, we sought to determine the independent and integrated value of maximal MBF and CFR in assessing the future risk of cardiovascular mortality.
METHODS

Study Population
All consecutive patients referred for a rest/stress cardiac positron emission tomographic (PET) scan for stable symptoms at Brigham & Women's Hospital (Boston, MA) between January 1, 2006, and December 31, 2013, were included in this study, excluding patients with prior heart transplantation, healthy research participants, and those whose images were missing or uninterpretable owing to poor image quality. In all, 486 unique patient studies from 2006 to 2013 were not interpretable because of poor image quality or technical issues and were thus excluded. In cases of repeat PET evaluations during the study period, only the earliest evaluable study was included. The study was approved by the Partners Healthcare Institutional Review Board with waiver of informed consent and conducted in accordance with the institutional guidelines. Demographic factors and key elements of the patient's history, including risk factors and medication use, were ascertained at the time of the study by patient interview and review of medical records.
PET Imaging
A standard PET-computed tomography scanner (Discovery RX or STE LightSpeed 64, GE Healthcare) was used to image all patients. Patients abstained from caffeine and methylxanthine-containing substances and drugs for 24 hours before their scans. Maximal hyperemic and resting MBF were measured with rubidium-82 (1480-2200 MBq) or N-13 ammonia (700-900 MBq) as the flow tracer, as described previously. 15, 16 A standard intravenous infusion of dipyridamole, adenosine, regadenoson, or dobutamine was used as the stress agent based on the prevailing preferred stress agent in our laboratory and patient characteristics, such as dobutamine in patients with chronic obstructive lung disease or asthma with wheezing and adenosine in patients with end-stage renal disease. Heart rate, blood pressure, and 12-lead ECG were recorded at baseline and every minute during and after pharmacological stress. Maximal hyperemic and resting MBF (in ml·g
were computed from the dynamic stress and rest imaging series, respectively, using compartmental tracer kinetic modelling and commercially available software (Corridor4DM), as described previously. [15] [16] [17] CFR for each patient was calculated as the ratio of maximal MBF at peak hyperemia to resting MBF for the entire left ventricle. The results of CFR and MBFs were not reported clinically and, hence, did not influence downstream clinical decision making.
Using a standard 5-point scoring system, semiquantitative 17-segment assessment of the gated myocardial perfusion images was performed by experienced observers. 18 Summed rest and stress scores were calculated as the sum of individual
Clinical Perspective
What Is New?
• In patients with known or suspected coronary heart disease, coronary flow reserve is a stronger independent predictor of cardiovascular mortality than absolute maximal myocardial blood flow beyond traditional cardiovascular risk factors, hemodynamic load (rate-pressure product), myocardial scar/ischemia, left ventricular ejection fraction, and revascularization after scan.
• Integrated noninvasive physiological assessment of coronary circulatory function with concordant or discordant impairment of coronary flow reserve and maximal myocardial blood flow identifies unique prognostic phenotypes in stable coronary artery disease.
What Are the Clinical Implications?
• Impaired coronary flow reserve with preserved maximal myocardial blood flow identifies patients at an increased risk of cardiovascular mortality despite lack of myocardial ischemia. Thus, these patients may be an appropriate target for initiation or intensification of lifestyle or pharmacological preventive therapies for cardiovascular risk reduction. Because women disproportionately represent this group, targeting it may help reduce the sex gap in cardiovascular outcomes.
• Preserved coronary flow reserve even in the presence of impaired maximal myocardial blood flow identifies low-risk patients with <1% annual cardiovascular mortality risk. Future trials are needed to identify whether a role for coronary revascularization exists in this low-risk cohort.
segmental scores on the respective images, and their difference was recorded as summed difference score, with higher scores reflecting larger areas of myocardial ischemia or scar. Summed rest, stress, and difference scores were converted into percentages of total myocardium by division, with the maximum possible score of 68 and multiplication by 100. Rest left ventricular ejection fraction (LVEF) was calculated from gated myocardial perfusion images with commercially available software (Corridor4DM).
Outcome Assessment
The vital status of all patients was ascertained by integrating data from the Social Security Administration' 
Statistical Analysis
All statistical analyses were performed with SAS 9.4 (SAS Institute Inc). A 2-sided P value <0.05 was considered statistically significant. In fully adjusted multivariable models, ≥1 covariate data value was missing in 44 out of 4029 (1%) unique patients, and they were excluded from multivariable analyses.
Assessment of Independent Prognostic Value of Maximal MBF and CFR
Univariable Cox proportional hazards models were used to assess the effect of flow variables on cardiovascular mortality. Ties in failure times were handled using Efron's approximation. The Wald χ-square statistic was used for inference testing. The proportional hazards assumption was examined by inclusion of a time-varying covariate term and was found to be valid. Extended multivariable Cox models were used to evaluate the independent effect of the flow variables on cardiovascular mortality after adjustment for age, sex, hypertension, diabetes mellitus, dyslipidemia, dialysis, body mass index, known CAD (including prior revascularization or prior myocardial infarction), LVEF (as a continuous variable), summed stress score (as an indicator for amount of myocardial scar or ischemia), revascularization after PET, rate-pressure product (resting systolic blood pressure × resting heart rate), and type of radiotracer or stress agent used for PET imaging. The variables for adjustment were selected based on the clinical knowledge. Revascularization after PET scan was ascertained from the Partners Healthcare Research Patient Data Registry, hospital records, and billing claims and was used as a time-varying covariate term for the adjustment in the analyses to account for the time to revascularization. To assess the independent effect of maximal MBF or CFR on cardiovascular mortality, these flow variables were used as continuous variables in 2 separate models: 1 model with CFR (without maximal MBF in the model) and the other model with maximal MBF (without CFR in the model).
Assessment of Integrated Prognostic Value of Maximal MBF and CFR
Integration of CFR and maximal MBF was achieved by creating 4 groups based on whether concordant or discordant impairment of these coronary flow indices occurred. CFR <2 and maximal MBF <1.8 mL·g
· min -1 were considered impaired. 13, 19 Annualized and cumulative cardiovascular mortality event rates in these 4 concordant or discordant groups were assessed using Poisson and Cox regression, respectively, both in univariable analyses as well as after adjustment for age, sex, hypertension, diabetes mellitus, dyslipidemia, dialysis, body mass index, known CAD, LVEF, summed stress score as an indicator for amount of myocardial scar or ischemia, revascularization within 90 days after PET scan, rate-pressure product, and type of radiotracer or stress agent used for PET imaging. In addition, the incremental value of 1 flow index over the other was also evaluated with flow indices as continuous variables. To assess the incremental effect of maximal MBF and CFR on cardiovascular mortality, these flow markers were added together in the same model as continuous variables. The correlation between maximal MBF and CFR (r = 0.55) did not preclude such an assessment (variance inflation factor for maximal MBF and CFR was 1.43; <5 indicated collinearity was not an issue between the variables in the model).
Exploratory Subgroup Analyses
Predefined subgroup analyses were carried out for independent and incremental prognostic value of maximal MBF and CFR for the following groups: age ≥ or < 65, sex, race (white or nonwhite), hypertension, diabetes mellitus, obesity (body mass index ≥30), known CAD, LVEF ≥ or < 50%, and presence of myocardial scar or myocardial ischemia.
Risk Reclassification
The potential impact of maximal MBF and CFR on risk stratification was assessed by net reclassification improvement 20 at 2 years follow-up. Threshold annual cardiovascular mortality rates of <1%, 1% to 3%, and > 3% were used for creating low-, intermediate-, and high-risk groups based on the American College of Cardiology/American Heart Association guidelines for the management of patients with stable ischemic heart disease. 21 Details of models used for risk reclassification are described in the online-only Data Supplement.
Sensitivity Analyses
Sensitivity analyses for the independent and incremental prognostic value of maximal MBF and CFR were carried out for all-cause mortality as the outcome. The primary analyses of interest were also investigated using Fine and Gray's 22 competing risk model to account for noncardiovascular death competing with cardiovascular death. The incremental prognostic value of maximal MBF was also tested within the subcategories of severely impaired (<1.5) and mild to moderately impaired (1.5-2) CFR.
RESULTS
Patient and Imaging Characteristics
Baseline patient and imaging characteristics for the overall study population (n = 4029) as well as when stratified by 4 groups with concordant or discordant impairment of CFR or maximal MBF are presented in Table 1 . Median age of the overall study population was 66 years, half were women (n = 2033, 50.5%), and a high prevalence of cardiovascular risk factors occurred. In all, 41% of patients had known CAD, and 10.1% of the patients underwent revascularization within 90 days after the PET scan. The main indications for PET scan were evaluation of chest pain and dyspnea. Seventy-one percent of patients had preserved LVEF (≥50%), and myocardial scar or ischemia burden was moderate with 29% of patients who had combined scar and ischemia burden of >10% of left ventricular myocardium. . The distribution of CFR and maximal MBF with superimposed distribution of cardiovascular deaths is illustrated as a scatterplot in Figure 1 .
Outcomes
After a median follow-up of 5.6 years, 1005 total deaths occurred (24.9% of the study population), of which 392 were cardiovascular deaths (9.7%) ( Table 2) . Patients who suffered cardiovascular death were, on average, older, were more likely to be male, and had a higher prevalence of hypertension, diabetes mellitus, obesity, known CAD, higher burden of myocardial scar and ischemia, lower LVEF, lower CFR, and lower maximal MBF compared with those who did not suffer cardiovascular death ( Figure 1 ). (Figure 2 ). Risk-reclassification analysis, described next, also supported the stronger independent prognostic value of CFR compared with maximal MBF.
Independent Prognostic Value of CFR and Maximal MBF
Integrated Prognostic Value of CFR and Maximal MBF
Crude annualized cardiovascular mortality rates showed a significant risk gradient for cardiovascular mortality in the 4 groups based on the concordant or discordant impairment of CFR and maximal MBF ( Figure 3A ). Annual cardiovascular mortality risk was 3.3% (95% CI, 2.9-3.7), 1.7% (95% CI, 1.3-2.1), 0.9% (95% CI, 0.6-1.6), and 0.4% (95% CI, 0.3-0.6), respectively, in patients with impairment of both CFR and maximal MBF, impaired CFR with preserved maximal MBF, preserved CFR with impaired maximal MBF, and when both CFR and maximal MBF were preserved ( Figure 3A) . In adjusted analysis, elevated cardiovascular mortality was independently driven by the impairment of CFR irrespective of whether the maximal MBF was impaired or preserved ( Figure 3B ). Adjusted annual cardiovascular mortality was 1.5% (95% CI. 1.0-2.3), 1.5% (95% CI, 1.0-2.3), 0.8% (95% CI, 0.4-1.4), and 0.5% (95% CI, 0.3-0.8), respectively, in patients with impairment of both CFR Data are presented as n (% of total patients in the group). Impaired coronary flow reserve was defined as <2. Impaired maximal myocardial blood flow was defined as <1.8 mL⋅g
. Vascular deaths include deaths related to aortic, mesenteric, renal vascular, or peripheral vascular disease, excluding coronary or cerebrovascular disease. and maximal MBF, impaired CFR with preserved maximal MBF, preserved CFR with impaired maximal MBF, and when both CFR and maximal MBF were preserved ( Figure 3B ).
Cardiovascular mortality event curves for the 4 groups with concordant or discordant impairment of CFR and maximal MBF are shown in Figure 4 . As seen with annualized cardiovascular mortality, a risk gradient for cumulative cardiovascular mortality hazard was observed across the 4 groups in unadjusted analysis ( Figure 4A ). At the end of 8.4 years of total follow-up time in the study, cumulative cardiovascular mortality rates were 19.6%, 11.3%, 6.4%, and 3.0%, respectively, in patients with impairment of both CFR and maximal MBF, impaired CFR with preserved maximal MBF, preserved CFR with impaired maximal MBF, and when both CFR and maximal MBF were preserved. Adjusted analysis revealed that the cardiovascular mortality risk was independently driven by the impairment of CFR but not by whether maximal MBF was preserved or impaired within a category of CFR ( Figure 4B ).
Modeling CFR and maximal MBF as continuous variables together in the same model to assess the incremental prognostic value of 1 coronary blood flow variable over the other further supported the stronger prognostic value of CFR over maximal MBF. In the analysis without adjustment for other clinical covariates, both CFR and maximal MBF were associated with cardiovascular mortality (HR, 2.40; 95% CI, 1.89-3.04; P<0.001 per unit decrease in CFR; and HR, 1.49; 95% CI, 1.25-1.77; P<0.001 per unit decrease in maximal MBF) (Figure 2 ). However, after adjustment for clinical covariates described earlier, CFR but not maximal MBF were associated with cardiovascular mortality (adjusted HR, 1.79; 95% CI, 1.38-2.31; P<0.001 per unit decrease in CFR after adjustment for maximal MBF and clinical covariates; and HR, 1.03; 95% CI, 0.84-1.27; P=0.8 per unit decrease in maximal MBF after adjustment for CFR and clinical covariates) (Figure 2 ).
Risk Reclassification
The addition of CFR to the pre-CFR model resulted in the reclassification of 9%, 29%, and 10% of patients at low, intermediate, and high cardiac risk, respectively ( Figure 
Exploratory Subgroup Analysis
The exploratory subgroup analysis showed a consistently stronger independent prognostic value of CFR for predicting cardiovascular mortality compared with maximal MBF across the subgroups studied ( Figure 5 ). In addition, CFR showed a consistent incremental prognostic value over maximal MBF in most of the subgroups studied (Figure 6 ). However, maximal MBF did Adjusted Cox model includes the following covariates: age, sex, hypertension, diabetes mellitus, dyslipidemia, dialysis, body mass index, known coronary artery disease, left ventricular ejection fraction, amount of myocardial scar/ischemia, revascularization after positron emission tomography scan, rate-pressure product, and type of radiotracer or stress agent.
not show incremental prognostic value over CFR in any of the subgroups studied ( Figure 6 ).
Sensitivity Analyses
The conclusions regarding the independent and incremental prognostic value of CFR and maximal MBF were unchanged when noncardiovascular death was included in the model as a competing risk for cardiovascular death ( Figure II in the online-only Data Supplement) or when allcause mortality was assessed as the outcome of interest ( Figure III in the online-only Data Supplement). In our primary analyses, a CFR <2 was used to define impaired CFR. The results were unchanged when an incremental prognostic value of maximal MBF was separately evaluated in groups of mild to moderately (1.5-2) or severely impaired (< 1.5) CFR ( Figure IV in the online-only Data Supplement).
DISCUSSION
In this large cohort of 4029 patients with known or suspected CAD and a median follow-up of 5.6 years, we found that CFR was a stronger independent predictor of cardiovascular mortality than maximal MBF. CFR, as a ratio of maximal to resting MBF, may better isolate vasodilator capacity and reduce systematic errors in the measurement of MBF. 9 This finding may partly explain the stronger independent prognostic value of CFR compared with maximal MBF.
Further, we showed that the integrated physiological assessment of coronary blood flow with groups based on the concordant or discordant impairment of CFR and maximal MBF identified unique prognostic phenotypes of patients. The group with concordantly impaired CFR and maximal MBF had the highest cardiovascular mor-A B tality (3.3% per year). This group of patients had the highest burden of myocardial scar and ischemia (47% patients in this group with scar + ischemia ≥10% of LV myocardium), suggesting significant underlying obstructive CAD. Our study design does not allow direct validation of the diagnostic utility of CFR and maximal MBF for differentiating epicardial obstruction from diffuse nonobstructive atherosclerosis and microvascular dysfunction because of a lack of cardiac catheterization data in the majority of patients. However, our study may provide risk-based guidance for decision of referral to cardiac catheterization. For example, in the group with concordantly impaired CFR and maximal MBF, the risk of cardiovascular death is high, as is the likelihood for multivessel disease. 23, 24 Therefore, angiographic (invasive or computed tomographic) evaluation may generally be necessary to define the specific phenotype of CAD (ie, predominantly obstructive CAD, diffuse nonobstructive atherosclerosis, and microvascular dysfunction). In contrast, the group with concordantly normal CFR and maximal MBF had the lowest cardiovascular mortality risk (0.4% per year) and are unlikely to have flow-limiting CAD; consequently, coronary angiography would rarely be necessary. The discussion on discordant groups follows.
Discordant Group With Impaired CFR and Preserved Maximal MBF
Patients with impaired CFR and preserved maximal MBF had an elevated cardiovascular mortality risk of 1.7% per year. The mechanism of increased risk of cardiovascular mortality in patients with impaired CFR and preserved maximal MBF (indicating high resting MBF) was not investigated in our study. However, the elevated cardiovascular mortality risk in these patients persisted even after correcting for the rate-pressure product, suggesting that the risk is dependent on factors beyond simply a hemodynamic effect from increased myocardial workload. The majority (608/873, 70%) of For the assessment of independent prognostic value, CFR or maximal MBF were modeled as continuous variables in separate models. Hazard ratios are expressed per unit decrease in CFR or maximal MBF. Hazard ratios are adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, dialysis, body mass index, known coronary artery disease, left ventricular ejection fraction, amount of myocardial scar/ischemia, revascularization after positron emission tomography scan, rate-pressure product, and type of radiotracer or stress agent. A particular variable is excluded from adjustment when it is subgroup of interest. CAD indicates coronary artery disease; CFR, coronary flow reserve; CI, confidence interval; HR, hazard ratio; and LVEF, left ventricular ejection fraction. this discordant group were women. The scar and ischemia burden was low, with a large area of scar and ischemia (≥10% LV myocardium) present in only 15% of patients in this group, suggesting predominantly underlying nonobstructive CAD, a common phenotype in women with impaired CFR. 11 Further, the studies utilizing PET to measure MBF have shown that women have a higher resting MBF than men. 19, 25 Whether the elevated cardiovascular mortality risk in this group is a reflection of high cardiovascular risk inherent to women or is directly related to underlying flow alterations is not known. However, in our analysis, even after adjustment for various cardiovascular risk factors, the cardiovascular mortality in this group remained high, with adjusted cardiovascular mortality risk similar to that of the group with concordantly impaired CFR and maximal MBF. Therefore, an unmet need may exist for initiation or intensification of lifestyle and pharmacological preventive therapies for cardiovascular risk reduction in this group of patients that needs evaluation in randomized trials. Because women disproportionately represent this group, targeting it may help reduce the gender gap in cardiovascular outcomes.
Discordant Group With Preserved CFR and Impaired Maximal MBF
The patients with preserved CFR but impaired maximal MBF had a low risk of cardiovascular mortality (0.9% per year). This occurred despite significant scar and ischemia burden (scar + ischemia ≥10% LV myocardium in 30% of patients in this group), suggesting a higher prevalence of underlying obstructive CAD in this group. Because this is an observational cohort study, patients' risk was potentially modified by revascularization. However, even after adjustment for revascularization after scan, the cardiovascular mortality risk in this group of patients was low and similar to those with concordantly preserved CFR and maximal MBF (0.8% versus 0.5% per year, respectively; P=0.2). The observed low cardiovascular risk in patients with pre- Figure 6 . Exploratory subgroup analysis for incremental prognostic value of coronary flow reserve and maximal myocardial blood flow. For the assessment of incremental prognostic value, both CFR and maximal MBF were modeled together as continuous variables in the same model. Hazard ratios are expressed per unit decrease in CFR or maximal MBF. Hazard ratios are adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, dialysis, body mass index, known coronary artery disease, left ventricular ejection fraction, amount of myocardial scar/ischemia, revascularization after positron emission tomography scan, rate-pressure product, and type of radiotracer or stress agent. A particular variable is excluded from adjustment when it is subgroup of interest. CAD indicates coronary artery disease; CFR, coronary flow reserve; CI, confidence interval; HR, hazard ratio; and LVEF, left ventricular ejection fraction.
served CFR and impaired maximal MBF assessed globally for the entire LV myocardium parallels the coronary vascular territory-specific findings in the invasive literature. Patients with decreased fractional flow reserve (a ratio of 2 pressures under maximal hyperemia, thus reflecting a ratio of 2 maximal MBFs) but preserved coronary flow velocity reserve have predominantly focal epicardial stenosis but still have a low risk of adverse cardiovascular outcomes. 5, 26 Whether this group potentially represents patients who may be best served by optimal medical therapy for CAD management, with revascularization reserved for refractory symptoms, needs further investigation in clinical trials.
Limitations
Our study is a single-center observational study and, as such, has some inherent limitations. We adjusted our analyses for a large number of cardiovascular risk factors, but residual and unmeasured confounding likely occurred. We had broad inclusion criteria, but, given the large sample size, we were able to conduct exploratory subgroup analyses in various patient populations of clinical interest and found consistent results. Moreover, the broad inclusion criteria allow for increased generalizability of our findings. Last, because we studied patient-level outcomes in the form of cardiovascular mortality risk, the analysis was on a per-patient level (not a per-vessel level) based on the global CFR and maximal MBF for the entire LV myocardium.
CONCLUSIONS
CFR is a stronger predictor of cardiovascular mortality than maximal MBF. Integrated physiological assessment of coronary circulatory function based on the concordant or discordant impairment of CFR and maximal MBF identifies unique prognostic phenotypes of patients with known or suspected CAD.
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